ADPT Jan 2025 7.500 call
- GlobeNewswire
Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ® To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress
More than 20 abstracts will be presented from clinical trials and real-world evidence using clonoSEQ for MRD assessment across multiple types of blood cancersSEATTLE, May 31, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced that its next-generation sequencing (NGS)-based clonoSEQ® test for measurabl
- GlobeNewswire
Adaptive Biotechnologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
SEATTLE, May 29, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL. Adaptive Biotechnologies’ management is scheduled to participate in a fireside chat on Tuesday, June 11th at 10:20 a.m
- Simply Wall St.
Adaptive Biotechnologies First Quarter 2024 Earnings: Beats Expectations
Adaptive Biotechnologies ( NASDAQ:ADPT ) First Quarter 2024 Results Key Financial Results Revenue: US$41.9m (up 11...
